Chemotherapy resistance and stemness in mitotically quiescent human breast cancer cells identified by fluorescent dye retention by Quayle, L.A. et al.
This is a repository copy of Chemotherapy resistance and stemness in mitotically 
quiescent human breast cancer cells identified by fluorescent dye retention.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/138651/
Version: Published Version
Article:
Quayle, L.A., Ottewell, P.D. orcid.org/0000-0002-4826-0771 and Holen, I. 
orcid.org/0000-0002-8759-6913 (2018) Chemotherapy resistance and stemness in 
mitotically quiescent human breast cancer cells identified by fluorescent dye retention. 
Clinical & Experimental Metastasis. ISSN 0262-0898 
https://doi.org/10.1007/s10585-018-9946-2
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Vol.:(0123456789) 
Clinical & Experimental Metastasis 
https://doi.org/10.1007/s10585-018-9946-2
RESEARCH PAPER
Chemotherapy resistance and stemness in mitotically quiescent 
human breast cancer cells identiied by luorescent dye retention
Lewis A. Quayle1 · Penelope D. Ottewell1 · Ingunn Holen1
Received: 20 July 2018 / Accepted: 26 October 2018 
© The Author(s) 2018
Abstract
Metastatic recurrence in breast cancer is a major cause of mortality and often occurs many years after removal of the primary 
tumour. This process is driven by the reactivation of disseminated tumour cells that are characterised by mitotic quiescence 
and chemotherapeutic resistance. The ability to reliably isolate and characterise this cancer cell population is critical to 
enable development of novel therapeutic strategies for prevention of breast cancer recurrence. Here we describe the iden-
tiication and characterisation of a sub-population of slow-cycling tumour cells in the MCF-7 and MDA-MB-231 human 
breast cancer cell lines based on their ability to retain the lipophilic luorescent dye  Vybrant® DiD for up to six passages in 
culture.  Vybrant® DiD-retaining (DiD+) cells displayed signiicantly increased aldehyde dehydrogenase activity and exhib-
ited signiicantly reduced sensitivity to chemotherapeutic agents compared to their rapidly dividing,  Vybrant® DiD-negative 
(DiD−) counterparts. In addition, DiD+ cells were exclusively capable of initiating population re-growth following with-
drawal of chemotherapy. The DiD+ population displayed only partial overlap with the  CD44+CD24−/low cell surface protein 
marker signature widely used to identify breast cancer stem cells, but was enriched for  CD44+CD24+ cells. Real-time qPCR 
proiling revealed diferential expression of epithelial-to-mesenchymal transition and stemness genes between DiD+ and 
DiD− populations. This is the irst demonstration that both MCF-7 and MDA-MB-231 human breast cancer lines contain a 
latent therapy-resistant population of slow-cycling cells capable of initiating population regrowth post-chemotherapy. Our 
data support that label-retaining cells can serve as a model for identiication of molecular mechanisms driving tumour cell 
quiescence and de novo chemoresistance and that further characterisation of this prospective tumour-reinitiating population 
could yield novel therapeutic targets for elimination of the cells responsible for breast cancer recurrence.
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Abbreviations
BMP1  Bone morphogenetic protein 1
BrdU  Bromodeoxyuridine 
(5-bromo-2’-deoxyuridine)
CD24  Cluster of diferentiation 24
CD44  Cluster of diferentiation 44 (hyaluronan 
receptor)
CDH1  Cadherin 1, type 1, E-cadherin (epithelial)
CDH2  Cadherin 2, type 1, N-cadherin (neuronal)
CSC  Cancer stem cell
CTNNB1  Catenin (cadherin-associated protein), beta 1
DEAB  Diethylaminobenzaldehyde 
(4-Dimethylaminobenzaldehyde)
DiD-  Vybrant® DiD-negative (non-label-retaining), 
fast-cycling cell
DiD+  Vybrant® DiD-positive (label-retaining), slow-
cycling cell
EdU  Ethynyldeoxyuridine 
(5-ethynyl-2’-deoxyuridine)
EGFR  Epidermal growth factor receptor
EMT  Epithelial-to-mesenchymal transition
FZD7  Frizzled family receptor 7
IC95  95% Inhibitory concentration
JAG1  Jagged 1
MET  Mesenchymal-to-epithelial transition
NOTCH1  Notch 1
SMAD2  SMAD family member 2
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SNAI2  Snail homolog 2
TGFB1  Transforming growth factor, beta 1
TGFB2  Transforming growth factor, beta 2
TGFB3  Transforming growth factor, beta 3
WNT5B  Wingless-type MMTV integration site family, 
member 5B
VIM  Vimentin
Introduction
Metastatic recurrence in advanced breast cancer is a major 
cause of patient morbidity and mortality. A substantial body 
of evidence indicates that metastatic foci are initiated by 
a latent sub-population of cancer cells that are capable of 
surviving adjuvant chemotherapy and colonising distal sites, 
where they may remain dormant for several years before 
emerging to reinitiate tumour growth [1]. The inability to 
remove this population, often referred to as cancer stem cells 
(CSCs), has proved to be the major obstacle in developing 
truly curative treatments for advanced breast cancer, with 
15-year recurrence rates remaining as high as 40% [2].
Given that traditional chemotherapeutic agents are reli-
ant on mitotic activity to initiate cytotoxicity, it has been 
proposed that CSCs, like their non-malignant counterparts, 
exist in a slow-cycling state of relative mitotic quiescence 
that confers an inherent ability to survive chemotherapy. 
Indeed, the slow-cycling status of adult stem cell populations 
identiied in the brain, skin and intestine has been transi-
tively linked to their observed survival during chemotherapy 
and their subsequent ability to regenerate tissue following 
chemotherapy withdrawal [3–5]. Analogous populations of 
slow-cycling cells have been identiied in multiple cancer 
types. Yumoto et al. [6] described the identiication of slowly 
cycling sub-populations in a number of human prostate can-
cer cell lines based on their persistent retention of luorescent 
lipophilic dye. Expanding on these indings, Wang et al. [7] 
demonstrated that label-retaining prostate cancer cells dif-
ferentially up-regulate expression of various haematopoietic 
stem cell niche-associated markers and were signiicantly 
more metastatic in vivo when compared to the rapidly divid-
ing cell population isolated from the same parental culture. 
Dembinski and Krauss [8] similarly reported that a slow-
cycling population of label-retaining pancreatic adenocarci-
noma cells demonstrated morphological and transcriptomic 
changes indicative of epithelial-to-mesenchymal (EMT) 
transition and were ten-fold more tumourigenic in vivo than 
the non-label retaining population. Label-retaining popula-
tions have also been identiied in melanoma, brain, ovar-
ian, colon and breast cancer cell lines [9–12]. However, the 
link between these slow-cycling, label-retaining populations 
and chemoresistance has remained largely unstudied and it 
remains unclear whether label-retaining cells represent a 
tumour recurrence-initiating population.
In this study, we demonstrate the novel application of 
 Vybrant® DiD for identiication, isolation and characterisa-
tion of a latent, slow-cycling, label-retaining cell popula-
tion in the oestrogen receptor-positive MCF-7 and triple-
negative MDA-MB-231 human breast cancer cell lines. We 
demonstrate that these slow-cycling cells are signiicantly 
more resistant to conventional chemotherapeutic agents 
than their rapidly dividing counterparts and importantly, 
that label-retaining cells are exclusively capable of active 
proliferation following removal of chemotherapeutic drugs, 
implying their ability to drive tumour recurrence. Our data 
support that label-retaining cells can serve as a model for 
identiication of molecular mechanisms driving tumour cell 
quiescence and de novo chemoresistance.
Materials and methods
Cell culture
MCF-7 and MDA-MB-231 human breast cancer cell lines 
were sourced directly from the American Type Culture Col-
lection (ATCC) (Manassas, Virginia, USA) as fully authen-
ticated cryogenically frozen cultures. Cells were routinely 
maintained in vitro as adherent cultures grown in complete 
growth medium composed of RPMI-1640 basal medium 
(11 mM glucose, 2 mM L-glutamine) (Life Technologies 
Ltd., Paisley, U.K.) supplemented with 10% (v/v) foetal 
bovine serum (FBS) (Life Technologies Ltd.).
Fluorescent dye labelling, label retention assays 
and luorescence‑activated cell sorting
Vybrant® DiD labelling was performed according to the 
manufacturer’s instructions for labelling cells in suspension 
(Molecular Probes MP22885) using 1.0 × 106 cells per ml of 
serum-free basal culture medium.
Labelled samples were grown as adherent cultures for up 
to six consecutive passages post-staining, with sub-culture 
being undertaken at approximately 80% of the duration of 
the logarithmic phase of culture growth. At each sub-culture 
interval, samples of 1.0 × 106 cells were prepared in serum-
free basal medium and used to assess the degree of  Vybrant® 
DiD staining present within each sample. Cytoluorimetric 
analyses were undertaken using the BD™ LSR-II™ plat-
form (Beckton, Dickenson and Co. Plc., Oxford, UK). 
Fluorescence activated cell sorting (FACS) was undertaken 
using the BD™ FACSAria™ platform (Beckton, Dickenson 
and Co. Plc.) after six consecutive passages of culture post-
labelling. Cytoluorimetric analysis and FACS platforms 
were calibrated at the outset of each experiment to enable 
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detection of  Vybrant® DiD-negative (DiD-) and -positive 
(DiD+) cells. Negative control samples consisting of cells 
that had never been exposed to  Vybrant® DiD were irst used 
to set the gate for the detection of DiD− events. All cells 
subsequently identiied as DiD− had therefore completely 
lost their initial label and possessed a luorescence intensity 
equivalent to that of an unlabelled cell population. Positive 
control samples consisting of cells that had been freshly 
labelled with  Vybrant® DiD were then used to set the gate 
for detection of DiD+ cells. All cells subsequently identiied 
as DiD+ (dye-retaining) therefore possessed a luorescence 
intensity equivalent to that of a dye-saturated cell population 
immediately post-labelling. The general gating tree for iden-
tiication, diferential low cytometric analysis and isolation 
of DiD− and DiD+ cells is shown in Supplementary Fig. 1.
Flow cytometric assays
In order to analyse the cell cycle proile of live DiD− and 
DiD+ cells, unsorted samples were prepared at 1.0 × 106 
cells per ml in serum-free basal culture medium from 
labelled cultures at six passages post-staining. Hoechst 
33342 stock solution (Life Technologies Ltd.) was added 
to samples at a inal concentration of 5 µg/ml and incuba-
tion undertaken at 37 °C for 45 min in total darkness prior 
to analysis.
Aldehyde dehydrogenase (ALDH) activity was deter-
mined using the non-immunological ALDEFLUOR™ assay 
kit (STEMCELL™ Technologies U.K. Ltd., Cambridge, 
U.K.) according to the manufacturer’s instructions (STEM-
CELL™ Technologies Document 29888) using unsorted 
cultures at six passages post-staining with  Vybrant® DiD. 
Samples of unlabelled cells treated with the speciic ALDH 
inhibitor diethylaminobenzaldehyde (DEAB) were prepared 
in an identical manner concomitantly as control samples 
used to allow deinition of the gating strategy and to control 
for autoluorescence by setting the appropriate photomul-
tiplier tube voltage for detection of negative events within 
each channel.
In order to analyse the expression of breast CSC markers, 
unsorted  Vybrant® DiD-labelled samples at passage six post-
labelling were stained with mouse monoclonal IgG1 anti-
human CD24-phycoerythrin (Abcam Plc., Cambridge, U.K., 
clone SN3, product code ab77219) and mouse monoclonal 
IgG2b anti-human CD44-Brilliant Violet 421™ (Beck-
ton, Dickenson and Co. Plc., clone G44-26, product code 
562890) primary antibodies concomitantly. The inal work-
ing concentration of each antibody was 6 µg/ml and 10 µg/
ml, respectively. Matched isotype control samples were pre-
pared using phycoerythrin-conjugated mouse monoclonal 
IgG1 (Abcam Plc., clone B11/6, product code ab91357) and 
Brilliant Violet 421™-conjugated mouse monoclonal IgG2b 
(Beckton, Dickenson and Co. Plc., clone 27–35, product 
code 562748) isotype control antibodies. Each isotype con-
trol antibody was used at the same working concentration as 
the primary antibody to which it was matched. Briely, sam-
ples of 1.0 × 106 live cells were prepared from harvested cell 
cultures and washed twice by resuspension in low cytom-
etry bufer (5% (v/v) FBS in PBS). Washed cell pellets were 
resuspended in 100 µl of primary or isotype control antibody 
solution (pre-diluted to the desired concentration in low 
cytometry bufer) and incubated for 1 h at 4 °C in total dark-
ness under constant agitation. Samples were then washed 
three times, resuspended in 1 ml of low cytometry bufer 
and passed through a 40 µm cell strainer prior to immediate 
cytoluorimetric analysis.
Immunoluorescence
Vybrant® DiD− and DiD+ cells were sorted at passage 
six post-labelling of cultures and 2000 sorted cells depos-
ited onto Superfrost Plus™ glass microscopy slides by 
cytocentrifugation (150xg for 3 min using medium accel-
eration) using the Shandon™ Cytospin™ 3 cytocentrifuge 
(Thermo Fisher Scientiic, Paisley, UK). Samples were ixed 
in 4% (w/v) paraformaldehyde on ice for 10 min, washed 
in two changes of PBS, and permeabilised in 0.1% (v/v) 
Triton™ X-100 in PBS. Samples were washed three times 
using PBS-Tween® 20 (PBST) (0.01% (v/v)  Tween® 20 in 
PBS) and blocked in a solution of 10% (v/v) normal goat 
serum + 1% (w/v) bovine serum albumin (BSA) in PBST 
at ambient temperature for 1 h. Immunostaining for Ki67 
expression was undertaken using an unconjugated rabbit 
polyclonal IgG anti-human Ki67 primary antibody (Abcam 
Plc., product code ab15580) diluted in in 1% (w/v) BSA in 
PBST to a inal working concentration of 1 µg/ml. Matched 
isotype control samples were prepared using an uncon-
jugated rabbit polyclonal IgG isotype control antibody 
(Abcam Plc., product code ab171870) and were used at 
the same inal working concentration as the primary anti-
body. Incubation was undertaken inside of a humidiied 
slide tray overnight at 4 °C. Following three more washes 
in PBST, primary antibody staining was localised using an 
 AlexaFluor®488-conjugated goat polyclonal anti-rabbit IgG 
secondary antibody (Abcam Plc., product code ab150077) 
diluted in in 1% (w/v) BSA in PBST to a inal working con-
centration of 4 µg/ml. Incubation was undertaken for 1 h at 
ambient temperature. Three further washes in PBST were 
undertaken before samples were mounted using  ProLong® 
Gold anti-fade mounting medium containing 4މ,6-diamidino-
2-phenylindole (DAPI) (Life Technologies Ltd.).
Chemotherapy resistance assays
Cultures were labelled with  Vybrant® DiD and grown 
for ive consecutive passages post-staining before being 
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seeded into triplicate wells of six-well cluster plates. All 
plates were placed into incubation for a period of 24 h 
post-seeding prior to treatment with either pegylated lipo-
somal doxorubicin (Clinical Research Pharmacy, Weston 
Park Hospital, Sheield, U.K.) or paclitaxel (Abcam Plc.) 
at the pre-determined  IC95 concentration (2.36 µM and 
46.45 nM, respectively, for MCF-7 cells and 0.32 µM and 
20.80 nM, respectively, for MDA-MB-231 cells). These 
concentrations were established using drug dose–response 
curves generated using the MTT assay (Supplementary 
Fig. 2) as previously described [13]. After 72 h, drug-con-
taining medium was removed from cultures and  Vybrant® 
DiD content analysed cytofluorimetrically.  Vybrant® 
DiD− and DiD+ populations were sorted by FACS and 
deposited directly into triplicate wells of six-well plates 
containing drug-free culture medium at a clonogenic 
density of 200 cells per well. Plates were incubated for a 
period equivalent to at least six log-phase doubling times 
prior to colony formation being assayed. Colonies were 
ixed in a 4% (w/v) paraformaldehyde in PBS for 15 min 
at ambient temperature. Fixative was then removed and 
colonies stained with 0.05% (w/v) aqueous crystal vio-
let solution (Merck Chemicals Ltd., Nottingham, U.K.) 
for 30 min at ambient temperature. Plates were imaged 
using the Pixera Professional 1.2 megapixel digital camera 
system (Pixera UK Ltd., Bourne End, UK) and colonies 
counted by way of semi-automated image analysis using 
GeneTools software (Syngene U.K. Ltd., Cambridge, UK).
Real‑time qPCR
Total RNA was isolated from DiD− and DiD+ cells at 
passage six post-labelling of cultures using the miRNeasy 
Micro Kit (Qiagen UK, Manchester, UK) according to the 
manufacturer’s instructions. During FACS, each population 
was sorted directly into separate tubes containing 700 µl of 
 QIAzol® lysis reagent. Following extraction of RNA, cDNA 
was synthesised using the  RT2 First Strand Kit (Qiagen) and 
real-time qPCR carried out using  RT2 SYBR Green ROX™ 
qPCR Mastermix (Qiagen) according to the manufacturer’s 
instructions. The complete PCR reaction mixture (Master-
mix + cDNA synthesis product) was dispensed as 10 µl vol-
umes into the wells of a 384-well  RT2 custom PCR array 
containing pre-dispensed primers (information for primers 
is available in Supplementary Table 1). A total of 1.25 ng 
of cDNA was used per 10 µl reaction. The real-time qPCR 
ampliication protocol was run on an Applied Biosystems 
7900-HT real-time cycler and was as follows: 95 °C for 
10 min (1 cycle) followed by 15 s at 95 °C and 1 min at 
60 °C (40 cycles). Dissociation (melting) curve analysis was 
carried out at the end of each run using the default melting 
curve programme of the cycler.
Statistical analyses
All data are expressed as the mean ± the standard error of the 
mean (SEM). All statistical analyses were undertaken using 
GraphPad Prism 7 (GraphPad Software Inc., La Jolla, USA). 
The statistical analysis applied to data, where undertaken, 
is indicated within the respective igure legend. Statistical 
signiicance was attributed when P < 0.05.
Results
Vybrant® DiD is well suited to long‑term lineage 
tracing
The lipid intercalating long alkyl side-chain carbocyanine 
derivatives, such as the  Vybrant® and structurally analo-
gous PKH dye series, are by far the most frequently used 
supravital lipophilic luorochromes for cell tracing and track-
ing applications in cancer studies [14, 15]. When present 
within biological membranes, dyes of both series charac-
teristically exhibit strong luorescence and photostability 
as a result of their extremely high extinction coeicients, 
modest quantum yields, and short excited-state lifetimes 
within lipid environments, making their lipid intercalating 
and photochemical properties ideally suited to long-term lin-
eage tracing applications [16, 17]. However, the potential for 
confounding results due to inadvertent lateral dye transfer, 
cytotoxicity and loss of cellular function following initial 
staining is greater when using PKH rather than  Vybrant® 
dyes based on literary reports [15, 18]. In addition, the initial 
labelling of cells with PKH dyes requires resuspension of 
cells in an isosmotic mannitol-based loading medium while 
the  Vybrant® dyes can be added directly to culture medium, 
making handling less complicated and permitting uniform 
labelling of cells either in suspension or when growing as 
adherent monolayers [19].  Vybrant® DiD was chosen for 
further assessment of suitability for lineage tracing from 
the  Vybrant® dyes commonly used for such experiments 
 (Vybrant® DiO, DiI, CM-DiI and DiD) based on prelimi-
nary experiments showing that none of these dyes adversely 
afected cell culture growth, colony formation or migra-
tory capability, but that  Vybrant® DiD resulted in the most 
intensely luorescent staining (data available upon request).
Initial experiments designed to assess the eiciency of 
cellular  Vybrant® DiD uptake and its efects on tumour cell 
viability were carried out using the highest supplier-rec-
ommended concentration of 5 µM. The percentage of posi-
tively labelled and viable cells in MCF-7 and MDA-MB-231 
cultures was determined cytoluorimetrically immediately 
after DiD staining. Both MCF-7 and MDA-MB-231 cultures 
were 100% DiD positive (Supplementary Fig. 3a) and there 
was no signiicant diference in culture viability between 
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unstained and DiD-stained cells in either cell line, as deter-
mined by cytoluorimetric assessment of propidium iodide 
uptake (Supplementary Fig. 3b). Next, the efects of DiD 
staining on the proliferation of MCF-7 and MDA-MB-231 
cell lines was assessed by haemocytometric counting of 
viable cell number in unstained and DiD-stained cultures 
at 24-h intervals; no signiicant diferences were detected 
at any time point in either cell line, conirming that the cell 
labelling protocol had no adverse efects on cell viability and 
growth (Supplementary Fig. 3c).
As the identiication of cells with reduced mitotic activ-
ity by label-retention assays is critically dependent on dilu-
tion of luorescent dye from actively proliferating cells, the 
degree of luorescence in a labelled culture must negatively 
correlate with culture expansion. In order to determine the 
efects of cell proliferation on DiD intensity, the luorescent 
signal of DiD-stained MCF-7 and MDA-MB-231 cultures 
was measured immediately post-staining and then again 
at the end of the logarithmic phase of one passage of cul-
ture growth (4 days in both instances). The resultant data 
conirmed that as the number of cells within each culture 
expanded, there was a reciprocal reduction in the intensity 
of DiD luorescence (Supplementary Fig. 3d), demonstrat-
ing that the retention of DiD inversely correlates with net 
mitotic activity.
Human breast cancer cultures contain 
a label‑retaining sub‑population
In order to determine whether DiD was progressively 
diluted from cultures over subsequent passages of growth, 
MCF-7 and MDA-MB-231 cells were stained with DiD 
and the proportion of dye-retaining cells analysed by low 
cytometry at the point of sub-culture over six consecutive 
passages. As was previously observed, 100% of cells were 
initially positive for DiD (Fig. 1a, b). After three passages 
in culture, the mean number of dye-stained cells began to 
decrease (Fig. 1b). After ive passages, the mean number of 
DiD− cells had exceeded 50%, while DiD+ cells accounted 
for 2.37 ± 0.05% of the total cell population in MCF-7 cul-
tures and 1.56 ± 0.24% in MDA-MB-231 cultures (Fig. 1b, 
c). At this point, dye-retaining DiD+ cells were easily dis-
tinguishable from those cells that had lost their initial DiD 
label or those that retained only a low level of DiD stain-
ing by both low cytometry and luorescence microscopy 
(Fig. 1c, d).
A separate series of validation experiments were under-
taken to conirm that the decrease in the number of dye-
retaining cells was due to division (and conversely that 
retention was due to reduced mitotic activity); cells were 
growth-arrested by pre-treatment with mitomycin C (10 µg/
ml for 3 h) prior to  Vybrant® DiD-labelling and the number 
of dye-retaining cells in both growing and growth-arrested 
cultures measured over time. No signiicant reduction in the 
number of dye-stained cells in mitomycin C-treated cultures 
were observed over the entire assay period, while the num-
ber of dye-retaining cells in growing cultures was reduced 
to ≤ 0.1% after six passages, in accordance with previous 
observations (Fig. 1e).
Label‑retaining MCF‑7 and MDA‑MB‑231 cells are 
slow‑cycling
The mean fluorescence intensity of DiD− (mean fluo-
rescence = 309.3 ± 9.7 RFU for MCF-7 and 341.7 ± 8.67 
RFU for MDA-MB-231) and DiD+ (mean fluores-
cence = 39,766 ± 1143 RFU for MCF-7 and 38,315 ± 2190 
RFU for MDA-MB-231) cell populations after six consecu-
tive passages was used to calculate the cell cycle time of 
DiD+ cells relative to DiD− cells (Fig. 2a). The DiD+ popu-
lation was determined to lag behind the DiD− population by 
~ 7 divisions in both cell lines. Subsequent live cell cycle 
analysis in the MCF-7 cell line revealed a signiicant 5.43% 
and 7.13% increase in the number of DiD+ cells in the S- 
and  G2/M-phases of the cell cycle, respectively, compared to 
their DiD− counterparts. A signiicant 16.90% reduction on 
the  G0/G1 fraction in DiD+ MCF-7 cells was also observed 
(Fig. 2b). Analysis of Ki67 immunostaining revealed a 
signiicant 49.10% decrease in the expression of Ki67 in 
the DiD+ population compared to the DiD− population 
(Fig. 2c). Similarly, live cell cycle analysis in the MDA-
MB-231 cell line showed a signiicant 11.33% increase in 
the number of DiD+ cells in the  G2/M-phase of the cell cycle 
compared to their DiD− counterparts, with a corresponding 
13.73% reduction in the  G0/G1 fraction (Fig. 2b). In addition, 
analysis of Ki67 immunostaining demonstrated a signiicant 
14.74% reduction in the expression of Ki67 in DiD+ MDA-
MB-231 cells compared with the DiD− MDA-MB-231 
population (Fig. 2d). Collectively, these indings suggest 
that the relatively slow-cycling status of the DiD+ popula-
tion is the net result of a greater number of  G0-arrested cells 
accompanied by extended  G2/M-phase transition or arrest.
Chemotherapy positively selects for repopulating 
label‑retaining cells
Slow-cycling cells would be predicted to be resistant to the 
efects of standard chemotherapies. In order to determine 
whether exposure to high doses of commonly used chemo-
therapeutic drugs would enrich for DiD+ cells due to their 
slow-cycling nature, cultures of MCF-7 and MDA-MB-231 
cells at passage ive post-staining were treated with the pre-
established  IC95 concentration of either doxorubicin or pacli-
taxel (see experimental outline in Fig. 3a). After one further 
passage in culture, vehicle treated control MCF-7 cultures 
had expanded approximately two-fold while MDA-MB-231 
 Clinical & Experimental Metastasis
1 3
control cultures had expanded approximately four-fold (data 
not shown). As expected, drug-treated cultures contained 
only a fraction of the total viable cell number present in the 
respective vehicle control (doxorubicin: MCF-7 = 5.51%, 
MDA-MB-231 = 1.88%; paclitaxel: MCF-7 = 6.40%, MDA-
MB-231 = 5.18%). Upon analysis for  Vybrant® DiD staining, 
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vehicle control-treated samples demonstrated the expected 
decrease in DiD+ cell content (reduced from 2.00 to 0.13% 
for MCF-7 and from 2.60 to 0.65% for MDA-MB-231) due 
to net dye dilution as the cultures continue to proliferate. 
In contrast, doxorubicin-treated (MCF-7 = 4.10-fold, MDA-
MB-231 = 21.65-fold) and paclitaxel-treated (MCF-7 = 3.77-
fold, MDA-MB-231 = 19.67-fold) samples demonstrated 
significant enrichment in DiD+ cell content (Fig.  3b). 
Collectively, these data demonstrate that slow-cycling 
DiD+ cells are less susceptible to chemotherapy-induced 
cytotoxicity than the rapidly-dividing DiD− cell population.
While the intrinsic ability of cancer cell populations to 
survive anti-neoplastic chemotherapy is clinically impor-
tant, those cells that are able to initiate disease relapse or 
recurrence must also be capable of subsequent proliferation. 
In order to establish whether cells that survived exposure 
to chemotherapy were able to divide and establish clonal 
populations following cessation of treatment, DiD− and 
DiD+ populations were isolated from vehicle control-, 
doxorubicin- and paclitaxel-treated cultures by FACS and 
re-plated at clonal density in drug-free growth medium (see 
experimental outline in Fig. 3a). After seven days, there 
was no signiicant diference in the colony forming abil-
ity of the DiD− and DiD+ fractions in untreated (control) 
MCF-7 and MDA-MB-231 cultures (data not shown). Strik-
ingly, a small proportion of DiD+ cells that had previously 
been exposed to either doxorubicin (MCF-7 = 0.76 ± 0.56%, 
M DA- M B - 2 3 1  =  1 . 9 9  ±  0 . 5 9 % )  o r  p a c l i t a xe l 
(MCF-7 = 2.62 ± 0.43%, MDA-MB-231 = 2.46 ± 0.43%) 
formed new colonies after 7 days following removal of 
drugs, whereas no colonies were formed by DiD− cells iso-
lated from either cell line post-treatment (Fig. 3c, d). When 
taken together, these data indicate that the slow-cycling sta-
tus of the DiD+ cell population is associated with enhanced 
resistance to conventional chemotherapeutic agents, and 
importantly that these cells are exclusively responsible for 
re-establishing the tumour cell population following cessa-
tion of treatment, mimicking tumour relapse.
Label‑retaining cells diferentially express putative 
breast cancer stem cell markers
Putative cancer stem cells have been shown to contribute 
to chemoresistance in a number of cancer types [20–23]. 
Given the established ubiquitous association of stemness 
and quiescence in the normal and neoplastic cellular hier-
archies and the slow-cycling and therapy-resistant nature of 
the DiD+ cell population, we next investigated whether DiD-
retaining cells displayed features of the purported breast can-
cer stem cell population.
ALDH has been successfully used as a marker for isola-
tion of stem-like cells from non-malignant tissue and multi-
ple cancer types. In particular, seminal studies by Ginestier 
et al. [24] and Charafe-Jaufret et al. [25] have demonstrated 
the utility of ALDH activity for isolation of stem cell-like 
populations from normal human breast tissue and breast 
carcinomas. We therefore measured the intrinsic ALDH 
activity of DiD− and DiD+ populations cytoluorimetri-
cally using the ALDEFLUOR™ assay. As shown in Fig. 4a, 
b, only 1.23 ± 0.14% of DiD− MCF-7 cells were  ALDH+, 
while this was increased (7.16-fold) to 8.81 ± 1.27% in the 
DiD+ population. Similarly, 3.50 ± 0.21% of DiD− MDA-
MB-231 cells were  ALDH+, while this was increased (2.19-
fold) to 7.68 ± 0.29% in the DiD+ population (Fig. 4c, d). 
These results demonstrate an overlap between the already 
described  ALDH+ breast cancer sub-population and the 
DiD+ population identiied here.
Along with ALDH, the  CD44+CD24−/low signature has 
also been widely used to demark a more tumourigenic popu-
lation of supposed breast CSCs since it was irst described 
by Al-Hajj et al. [26]. The co-expression of CD44 and CD24 
within DiD− and DiD+ populations was therefore exam-
ined. In the DiD− MCF-7 cell population, 0.95 ± 0.08% 
of cells exhibited the CSC-associated  CD44+CD24−/low 
phenotype, with the remainder of cells being distributed 
between  CD44−CD24−/low (1.64 ± 0.05%),  CD44−CD24+ 
(45.27 ± 1.44%) and  CD44+CD24+ (52.13 ± 1.39%) phe-
notypes (Fig. 4e, f). Notably, these fractions were not sig-
niicantly diferent in magnitude when compared to the 
relative size of each population measured in the parental 
MCF-7 cell population (data not shown). Interestingly how-
ever, while the size of the CSC-like  CD44+CD24−/low and 
 CD44−CD24−/low fractions remained unaltered when marker 
expression was measured in the DiD+ population, there 
was a signiicant 2.54-fold reduction in the  CD44−CD24+ 
population and corresponding 1.56-fold increase in the 
 CD44+CD24+ population (Fig. 4f). Moreover, almost the 
entire DiD− MDA-MB-231 population (99.45 ± 0.009%) 
was  CD44+CD24−/low while the remainder of cells 
Fig. 1  Identiication of Label-Retaining Cells In Vitro. a Cytoluori-
metric histograms illustrating dilution of  Vybrant® DiD in adherent 
human breast cancer cell cultures at passages 2, 4 and 6 of culture 
growth (P2, P4 and P6, respectively, where P = passage number). All 
cells were intensely positive immediately after staining (Day 0). Fluo-
rescent dye was lost from rapidly proliferating cells to reveal a popu-
lation of more slowly cycling label-retaining cells beyond passage 4. 
b Representative low cytometry plots depicting  Vybrant® DiD nega-
tive (DiD−) and positive (DiD+) populations in adherent MCF-7 and 
MDA-MB-231 cultures at passage six post-staining. c Cytoluori-
metrically determined percentage of  Vybrant® DiD-positive cells 
within adherent MCF-7 and MDA-MB-231 cultures over six consecu-
tive passages of culture growth (n = 3). d Analysis of  Vybrant® DiD 
retention in MDA-MB-231 cultures in the presence and absence of 
mitomycin C (MMC) over six consecutive passages of culture growth 
(n = 3). e Fluorescent and phase-contrast image overlay of MCF-7 
and MDA-MB-231 cultures at passage ive post-staining (scale bar 
= 100 µm). White arrows indicate DiD+ cells (red). All graphical data 
are expressed as mean ± SEM
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(0.55 ± 0.009%) were  CD44+CD24+ (Fig.  4g, h), again 
showing no signiicant diference with the proportional 
distribution of these markers measured in the parental cell 
line (data not shown). However, when the DiD+ population 
was analysed, a 1.40-fold reduction in  CD44+CD24−/low 
cells was measured, with a corresponding increase (52.41-
fold) in the  CD44+CD24+ population (Fig. 4h). When taken 
together, these data show that although a degree of overlap 
between the previously identiied CSC markers and slow-
cycling cells does exist, the slow-cycling label-retaining cell 
population are a distinct population of stem-like cancer cells.
Label‑retaining cells diferentially express EMT 
and stemness genes
Given the chemoresistant properties of the DiD+ popula-
tion and that they express markers associated with both 
mesenchymal and epithelial stemness, as has recently been 
associated with a more chemoresistant intermediate stem-
like phenotype (reviewed by Fabregat et al. [27]), expression 
of genes relating to EMT were investigated by quantitative 
real-time PCR proiling of the DiD+ population relative to 
the DiD− population. As can be seen in Fig. 5a, while the 
expression of SNAI2 and CDH1 by DiD+ MCF-7 cells was 
decreased relative to DiD− cells, as would be expected of 
the EMT-associated cadherin-switch [28], the corresponding 
increase in CDH2 and VIM expression that would classically 
be associated with complete EMT were not evident. Moreo-
ver, EGFR and WNT-signalling genes (CTNNB1, FZD7 and 
WNT5B) that have known roles in regulation of EMT were 
also modestly down-regulated relative to the DiD− MCF-7 
population. Interestingly, while components of TGFβ/BMP- 
(TGFB2/3 and SMAD2) and Notch-signalling (NOTCH1) 
were also down-regulated, three genes with known roles in 
functional diferentiation (TGFB1, BMP1 and JAG1) were 
found to be up-regulated. By contrast, expression of all 
genes measured remained largely stable between DiD− and 
DiD+ MDA-MB-231 populations, with the exception of up-
regulation of CDH2 in DiD+ MDA-MB-231 cells (Fig. 5b). 
Overall, these data indicate that slow-cycling DiD+ MCF-7 
cells may not have undergone complete EMT, while slow-
cycling DiD+ MDA-MB-231 cells largely share the tran-
scriptomic proile of the already mesenchymal-like parental 
cell line.
Discussion
In this report we have demonstrated that  Vybrant® DiD can 
be used for pulse-chase identiication and characterisation 
of an intrinsic sub-population of slow-cycling cells in breast 
cancer cell lines based on their ability to retain their initial 
 Vybrant® DiD label for an extended duration. Compared 
to the rapidly dividing bulk cell mass, the reduced mitotic 
capacity of the label-retaining sub-population was shown 
to be associated with an array of biologically and clinically 
relevant diferential characteristics. These included altera-
tions in the expression of CD44 and CD24 surface markers, 
increased ALDH activity, transcriptomic proiles indicative 
of an intermediate EMT-MET phenotype, a marked reduc-
tion in chemosensitivity and an exclusive capacity for re-
initiation of culture growth following cessation of exposure 
to chemotherapeutic agents. Collectively, these traits could 
signify that label-retaining cells are a population of cancer 
stem cells.
A number of previous studies have reported a signiicant 
expansion of the supposed cancer stem cell compartment 
following chemotherapy [8, 20–23]. Such enrichment would 
require either a large-scale expansion of the cancer stem cell 
population, or efective reduction of the bulk cell mass. A 
similar pattern of preferential proliferation or cytotoxicity 
would also be required to account for the signiicant increase 
in the relative proportion of slow-cycling, DiD+ cells sur-
viving following exposure to chemotherapy agents reported 
here. Calculation of the absolute number of DiD+ cells pre-
sent in MCF-7 cultures at the time of seeding and following 
exposure to a high concentration  (IC95) of chemotherapeu-
tic agents demonstrated an increase in the absolute label-
retaining DiD+ cell number from ~ 1000 cells at the time of 
seeding to ~ 3600 cells at the end of the assay period. Simi-
larly, in the MDA-MB-231 cell line the number of label-
retaining DiD+ cells increased from ~ 1600 to ~ 2800 across 
all treatment groups. These increases in label-retaining cell 
numbers most likely occurred due to mitotic division gener-
ating partially labelled daughter cells. However, such expan-
sion alone could not account for the signiicantly increased 
Fig. 2  Label-retaining cells are slow-cycling. a Cytoluorimetri-
cally determined mean luorescence intensity (RFU = relative luo-
rescence units) of  Vybrant® DiD-negative (DiD−) and DiD-positive 
(DiD+) MCF-7 and MDA-MB-231 populations at passage 6 post-
staining (n = 3). b Univariant cell cycle distribution of DiD− and 
DiD+ MCF-7 and MDA-MB-231 cells at 6 passages post-staining are 
shown; the percentage of cells within each population that are in  G0/
G1-phase (haploid chromosome number), S-phase (intermediate chro-
mosome number) and  G2/M-phase (diploid chromosome number) 
of the cell cycle are depicted (n = 3, two-way ANOVA with Sidak’s 
multiple comparison, ns = not statistically signiicant or P > 0.05, 
**** = P ≤ 0.0001). c Relative expression of Ki67 by DiD− and 
DiD+ MCF-7 cells (n = 3, unpaired t-test, ** = P ≤ 0.01). Representa-
tive images of immunostained cytocentrifuge preparations of DiD− 
and DiD+ MCF-7 cells isolated by FACS at passage 6 post-staining 
are shown; Ki67 staining (green) and nuclear counter-staining with 
DAPI (blue) are depicted (scale bar = 50 µm). d Relative expression 
of Ki67 by DiD− and DiD+ MDA-MB-231 cells (n = 3, unpaired 
t-test, *** = P ≤ 0.001). Representative images of immunostained 
cytocentrifuge preparations of DiD− and DiD+ MDA-MB-231 cells 
isolated by FACS at passage 6 post-staining are shown; Ki67 staining 
(green) and nuclear counter-staining with DAPI (blue) are depicted 
(scale bar = 50 µm). All graphical data are expressed as mean ± SEM
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relative proportion of DiD+ cells within each of the drug-
treated cultures compared to untreated cultures. These data 
not only demonstrate that label-retaining cells continued 
to proliferate when exposed to standard chemotherapeutic 
agents, but that the non-label-retaining DiD− cell popula-
tion was signiicantly more susceptible to drug-induced cell 
death than their slow-cycling DiD+ counterparts, resulting 
in a net enrichment for DiD+ cells. These conclusions mirror 
those drawn from similar in vitro studies reported by Moore 
et al. [11], who also demonstrated efective enrichment of a 
slow-cycling luorescent label-retaining population in vivo 
using clinically relevant doses of oxaliplatin and luorouracil 
to treat tumours derived from the HCT116 human colon 
cancer cell line.
While the intrinsic ability of cancer cell populations to 
survive anti-neoplastic chemotherapy is clinically impor-
tant, cells that are able to initiate tumoural relapse or disease 
recurrence must also be capable of subsequent proliferation. 
We therefore established that the DiD+ population were not 
avoiding the cytotoxic efects of doxorubicin or paclitaxel 
by entering a permanently non-dividing state of senescence, 
or that the onset of the cytotoxicity exerted by these drugs 
was simply delayed due to the slow-cycling nature of the 
label-retaining population. The formation of new clonal 
populations by label-retaining cells following cessation of 
exposure to chemotherapeutic drugs indicated that a propor-
tion of this sub-population was completely resistant to chem-
otherapy. These indings mirror those previously reported 
by Moore et al. [11], which showed that a sub-population 
of label-retaining cells could actively proliferate in vitro 
and in vivo shortly after halting oxaliplatin and luorouracil 
treatment. Moreover, the proportion of label-retaining cells 
that were able to form clonal populations following with-
drawal of chemotherapy in this study (~ 2% for both MCF-7 
and MDA-MB-231 across both chemotherapy drugs used) 
was several orders of magnitude larger than the proportion 
of cells previously demonstrated as being required to suc-
cessfully establish metastasis (0.001–0.02%) [29–31]. When 
taken together, these results indicate that slow-cycling cells 
not only survive during drug exposure but also are capable 
of reactivation after withdrawal of chemotherapy and could 
therefore potentially initiate either local tumoural relapse or 
formation of a secondary metastatic lesion.
Comparative live cell cycle profiling of DiD− and 
DiD+ populations indicated that DiD+ cells in both MCF-7 
and MDA-MB-231 cell lines were enriched for cells in 
the  G2/M-phase of the cell cycle. A number of instances 
of label-retaining cells having an increased  G2/M-fraction 
compared to their rapidly proliferating counterparts have 
been reported in the existing literature across various can-
cer types (breast, prostate, intestinal, myeloid cell, brain and 
ovarian) [7, 10, 11]. It has also previously been reported that 
such  G2/M-phase arrest is associated with multi-drug chem-
oresistance and a propensity to evade apoptosis [32, 33]. 
The latter observation implies that, while reduced mitotic 
activity itself is likely to contribute to the survival of label-
retaining cells in response to chemotherapy, it may not be 
the sole means by which de novo drug resistance occurs; 
growth arrest or slowed cell cycle transition could efec-
tively increase the time for drug elux, drug metabolism or 
repair of drug-induced cellular stress, and thereby enable 
evasion of pro-apoptotic signals in the relatively quiescent 
cell fraction. Indeed, this may have been a signiicant con-
tributory factor in the enhanced survival and enrichment of 
DiD+ cells in MCF-7 and MDA-MB-231 cultures treated 
with anti-neoplastic drugs. In support of this hypothesis, 
the expression of anti-apoptotic proteins has frequently been 
observed in quiescent normal and cancer stem cell popula-
tions and has been shown to contribute to their enhanced 
survival following chemotherapy [34]. Increased DNA 
damage repair pathway activation, up-regulation of xenobi-
otic drug pumps, and elevated enzymatic drug metabolism 
(particularly by ALDH) have also been reported in quies-
cent stem cell populations [35, 36], and we similarly found 
ALDH activity to be signiicantly up-regulated within the 
slow-cycling, chemotherapy-resistant DiD+ fraction of both 
MCF-7 and MDA-MB-231 cell lines.
Given the slow-cycling and therapy-resistant nature of 
the DiD+ cell fraction, it appears that there could be an 
associated between slow-cycling cells and the purported 
cancer stem cell population. A number of studies across 
various cancer types have transitively linked quiescence 
to the cancer stem cell phenotype through retrospective 
functional validation of putative cancer stem cell popula-
tions isolated using cell surface markers [12, 20, 37]. In 
contrast, studies in which the prospective identiication of 
a quiescent cell population was undertaken through label 
retention assays have demonstrated only partial overlap 
with cell surface marker signatures associated with the 
supposed cancer-type-speciic stem cell population [7, 8]. 
Our indings are in agreement with the latter reports; we 
Fig. 3  Label-retaining cells are resistant to chemotherapy. a Timeline 
for in  vitro determination of chemotherapy resistance in  Vybrant® 
DiD-negative (DiD−) and  Vybrant® DiD-positive (DiD+) sub-pop-
ulations. b Survival of DiD− and DiD+ MCF-7 and MDA-MB-231 
cell populations following 72-h continuous treatment with the  IC95 
concentration of either doxorubicin or paclitaxel (n = 3, unpaired 
t-test, *** = P ≤ 0.001, **** = P ≤ 0.0001). c Colony formation by 
doxorubicin- or paclitaxel-treated DiD− and DiD+ cells isolated from 
MCF-7 cultures following cessation of treatment (n = 3, unpaired 
t-test, ND = not detected, ns = not statistically signiicant or P > 0.05, 
** = P ≤ 0.01). Representative images of colony formation assays 
are also depicted. d Colony formation by doxorubicin- or paclitaxel-
treated DiD− and DiD+ cells isolated from MDA-MB-231 cultures 
following cessation of treatment (n = 3, unpaired t-test, ND = not 
detected, ** = P ≤ 0.01). Representative images of colony forma-
tion assays are also depicted. All graphical data are expressed as 
mean ± SEM
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observed only a modest increase in ALDH activity difer-
entiated the DiD− and DiD+ populations, and DiD+ cells 
were not enriched for the  CD44+CD24−/low putative 
breast CSC marker signature. Notably, the DiD+ sub-
population in both MCF-7 and MDA-MB-231 cell lines 
did show a signiicant enrichment with cells expressing 
the  CD44+CD24+ phenotype. The functional implications 
of enrichment for  CD44+CD24+ cells in the DiD+ popu-
lation and the nature of other cell sub-populations (e.g. 
DiD+ ALDH−) remain to be established. While the 
 CD44+CD24−/low surface marker signature and high 
ALDH activity have been widely used to identify the puta-
tive CSC population since the pioneering studies of Al-
Hajj et al. [26] and Ginestier et al. [24], respectively, more 
recent studies have demonstrated that the  CD44+CD24−/low 
and  ALDH+ marker profiles associated with putative 
breast CSCs identify minimally overlapping, spatiotem-
porally distinct populations across diferent breast cancer 
sub-types [38]. These studies exemplify that the concept 
of exclusive tumour cell sub-sets possessing increased 
nascent capacity for tumour propagation is still evolving. 
Another very notable example of this situation in breast 
cancer is that of the MDA-MB-231 cell line; data reported 
here and by others has shown that in excess of 99% of the 
total cell population express the  CD44+CD24−/low marker 
signature that is supposed to describe highly tumouri-
genic breast CSC, yet only a minority fraction of the cell 
population possesses the ability to initiate population re-
growth [39]. Indeed, an often overlooked inding of the 
landmark study undertaken by Al-Hajj et al. [26] was that 
 CD44+CD24+ breast cancer populations also remained 
viable and exhibited tumourigenicity in xenotransplanta-
tion studies but seemingly possessed reduced proliferative 
capacity compared to the  CD44+CD24−/low cells that were 
taken to represent the stem-like fraction. Based on these 
indings it seems plausible that the  CD44+CD24−/low sig-
nature was implicitly linked to enhanced tumourigenicity 
simply due to the rapid expansion of this population cou-
pled with an insuicient follow-up period in mice injected 
with  CD44+CD24+ cells, leading to the conclusion that 
the former exclusively possessed tumourigenic poten-
tial. In support of this, a number of other studies have 
indicated that stem cell activity in breast cancer is not 
exclusively limited to the  CD44+CD24−/low phenotype but 
that  CD44+CD24+ can be equally tumourigenic in mouse 
xenograft models, most notably illustrated by Meyer et al. 
[40] in oestrogen receptor-negative disease. Moreover, 
evidence from a more recent study indicates that CD24 
status has little bearing on tumourigenic potential in breast 
cancer and that  CD24−/low status can in fact reduce tumour 
initiation in some murine models [41]. Given the potential 
for a majority of cancer cells or numerous intrinsic sub-
populations to display tumourigenicity, we believe that 
the identiication of a slow-cycling and inherently therapy 
resistant cellular sub-set capable of leading to tumor recur-
rence is both biologically and clinically signiicant, inde-
pendent of a cancer stem cell model.
The use of  Vybrant® DiD to identify slow-cycling cancer 
cell populations is a simple and highly reproducible process 
that yields an easily identiiable population for isolation and 
further characterisation. In addition, the use of  Vybrant® 
DiD and analogous dyes ofers the additional distinct advan-
tage over other pulse-chase techniques (e.g. BrdU or EdU) of 
allowing live cells to be isolated, allowing functional studies 
to be carried out and comparisons to be made between the 
diferent populations. One drawback of this method is that 
suicient time in culture (several weeks) must elapse before 
label-retaining cells can be identiied. This factor has a sig-
niicant knock-on efect on it’s prospective utility for primary 
cultures, in that passaging this material multiple times could 
potentially alter the characteristics from those of the origi-
nal tissue. In addition, the capability of the dye-retaining, 
therapy-resistant cell population to form new tumours can 
ultimately only be demonstrated by implantation in vivo. 
On balance, however, this method does ofer the possibility 
of obtaining much more material for characterisation when 
compared to traditional means of identifying prospective 
stem-like cells, and the progressive dilution or retention of 
dye is reliant on a functional cellular phenotype that is inde-
pendent of the expression of protein markers with poorly 
understood functional roles in mitotic dynamics.
In summary, the work reported here details a highly 
reproducible and user-friendly method to enrich, isolate 
and characterise a live population of chemotherapy-resistant 
tumour cells based on a functional, mitotically quiescent 
phenotype. Further characterisation of this population could 
reveal biological programmes associated with mitotic quies-
cence and de novo drug resistance and thereby yield novel 
targets for therapies enabling elimination of the cells respon-
sible for breast cancer recurrence.
Fig. 4  Label-retaining cells diferentially express cancer stem cell 
markers. a Representative low cytometry plots depicting aldehyde 
dehydrogenase (ALDH) activity in DiD− and DiD+ MCF-7 sub-pop-
ulations. b Relative expression of ALDH by DiD− and DiD+ MCF-7 
cells (n = 3, unpaired t-test, ** = P ≤ 0.01). c Representative low 
cytometry plots depicting ALDH activity in DiD− and DiD+ MDA-
MB-231 sub-populations. d Relative expression of ALDH by 
DiD− and DiD+ MDA-MB-231 cells (n = 3, unpaired t-test, *** = 
P ≤ 0.001). e Representative low cytometry plots depicting CD24 and 
CD44 expression status of DiD− and DiD+ MCF-7 sub-populations. 
f Relative expression of CD24 and CD44 by DiD− and DiD+ MCF-7 
cells (n = 3, two-way ANOVA with Sidak’s multiple comparison, 
ns = P > 0.05, **** = P ≤ 0.0001). g Representative low cytometry 
plots depicting CD24 and CD44 expression status of  Vybrant® DiD− 
and DiD+ MDA-MB-231 sub-populations. h Relative expression of 
CD24 and CD44 by DiD− and DiD+ MDA-MB-231 cells (n = 3, two-
way ANOVA with Sidak’s multiple comparison, ND = not detected, 
**** = P ≤ 0.0001). All graphical data are expressed as mean ± SEM
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